|Wednesday, April 10, 2019|
The life sciences industry - pharmaceuticals, medical devices, diagnostics, vaccines and related businesses - is huge, growing and global, with international licensing, sales contracts, research and development agreements, and joint ventures. Each of these international ventures can lead to disputes, and well-positioned life sciences companies prefer international arbitration to litigation as the practical way to achieve confidential, widely enforceable judgments in a neutral setting.
Listen in as the International Chamber of Commerce’s (ICC) distinguished panel of speakers explain why international arbitration is the preferred dispute resolution mechanism for life sciences disputes, before they take a deeper dive into some of the complex issues that can arise in such disputes. Then join the ICC for a reception following the event.
4:30 – 5:00 pm | Registration
5:00 – 5:10 pm | Welcome and Introduction
Jared Hubbard, President, Boston International Arbitration Council; Counsel, Fitch Law Partners, Boston
Nancy M. Thevenin, General Counsel, USCIB/ICC USA
5:10 – 6:20 pm | Panel 1: Why International Arbitration for Life Sciences Disputes?
Rachael Kent, Partner, WilmerHale, Washington, DC
Marek Krasula, Counsel, ICC International Court of Arbitration®, New York
Carl Valenstein, Partner, Morgan Lewis, Boston
Conna Weiner, Vice-Chair, Northeast Arbitration Subcommittee, USCIB/ICC USA; Arbitrator and Mediator, JAMS, Boston and New York
6:20 – 7:30 pm | Panel 2: Complex Issues in Life Sciences Arbitration
J.P. Duffy, Partner, Baker McKenzie, New York
Greg Bell, Vice-President, Charles River Associates, Boston
Philip O’Neill, Chair, Northeast Arbitration Subcommittee, USCIB/ICC USA; Arbitrator, Boston
7:30 pm Networking reception